Empirical Finance’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Empirical Finance's VRTX Position: Q3 2026 in Review
Empirical Finance increased its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q3 2026, buying an estimated $99.3K and bringing the position to 9,180 shares worth $4.8M. The position accounts for 0.19% of the portfolio, ranked #105.
Empirical Finance first reported a position in VRTX in Q4 2016 and has held it in 29 quarters since. 1,796 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Empirical Finance held 9,180 shares of Vertex Pharmaceuticals worth $4.8M as of Q3 2026.
- Empirical Finance bought 194 Vertex Pharmaceuticals shares in Q3 2026, an estimated $99.3K.
- Vertex Pharmaceuticals made up 0.19% of Empirical Finance's portfolio in Q3 2026, its #105 holding.
- Empirical Finance first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 29 quarters since.
- 1,796 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Empirical Finance's 13F filing for Q3 2026, filed 13 Nov 2026.